{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:06:21Z","timestamp":1777928781076,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"abstract":"<jats:p>11 patients (aged 23\u201375 years) with refractory acute leukemia were treated at the Maine Medical Center with 5-Azacytidine, 150 mg\/m2\/day, by continuous infusion for 5 days every 2 weeks. Prior therapy included anthracycline\/cytosine arabinoside protocols. Of the 8 patients with refractory de novo acute myelogenous leukemia, 6 achieved remission at an overall response rate of 75% (3 complete remission and 3 partial remission). An average of 1.67 courses was necessary to achieve a response. Remissions were not seen in blastic chronic myelogenous leukemia nor in acute leukemia secondary to cytotoxic drugs. Toxicity included myelo-suppression, moderate nausea and vomiting, abnormal liver function tests, and neuromuscular symptoms. 5-Azacytidine by continuous infusion has significant activity in refractory acute myelogenous leukemia and should be considered for inclusion in primary remission induction therapy.<\/jats:p>","DOI":"10.1159\/000225641","type":"journal-article","created":{"date-parts":[[2009,6,12]],"date-time":"2009-06-12T10:29:57Z","timestamp":1244802597000},"page":"218-221","source":"Crossref","is-referenced-by-count":8,"title":["5-Azacytidine in Refractory Acute Leukemia"],"prefix":"10.1159","author":[{"given":"Delvyn C.","family":"Case, Jr.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,6,11]]},"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/225641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000225641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:21:20Z","timestamp":1777677680000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000225641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000225641","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,11]]}}}